The independent medical news service

Adding low-dose or hypofractionated radiotherapy to durvalumab plus tremelimumab offers no significant benefit to people with non-small-cell lung cancer that is resistant to PD-1 or PD-L1 inhibition, US study findings indicate.

Cutaneous immune-related adverse events are associated with a reduced risk for death among cancer patients with immune checkpoint inhibitors, research suggests.

The PD-L1 inhibitor sugemalimab has shown potential both as a consolidation treatment option for inoperable, locally advanced non-small-cell lung cancer as well as in combination with chemotherapy for the first-line treatment of metastatic disease.

Treatment with immune checkpoint inhibitors within 90 days of radiotherapy does not lead to a “meaningful increase” in rates of serious adverse events, say researchers who conducted a pooled analysis of US FDA registry data.

A post-hoc analysis of a randomized trial points to the benefit of adding metformin to an EGFR–tyrosine kinase inhibitor in advanced non-small-cell lung cancer patients with a BMI of at least 24 kg/m².

Quitting smoking around the time of receiving a lung cancer diagnosis is associated with significantly improved overall survival than continuing smoking, shows a meta-analysis published in the Journal of Thoracic Oncology.